Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case
The legal battle in the highly lucrative once-daily oral GLP-1 receptor agonist market has escalated significantly. Newly public Kailera Therapeutics, Inc. (NASDAQ: KLRA) has launched a direct challenge against Structure Therapeutics Inc. (NASDAQ: GPCR) over key intellectual property governing once-daily oral dosing.
On July 24, 2026, Kailera formally challenged Structure’s European patent, known as the '183 patent. The '183 patent is assigned to Structure’s wholly owned Delaware-incorporated subsidiary, Gasherbrum Bio Inc.
The Core of the Dispute: Once-Daily Dosing
The patent challenge centers on the specific chemical compounds and structural designs that enable once-daily oral dosing of small-molecule GLP-1 receptor agonists. Because oral bioavailability and tolerability are the primary hurdles for oral obesity drugs, patent protection over once-daily dosing compounds is of immense commercial value.
Structure is developing aleniglipron (GSBR-1290), which is scheduled to enter Phase 3 registration trials in Q3 2026. Kailera, which completed a massive $625 million IPO on April 16, 2026 (implied valuation of $2.1 billion), is aggressively advancing its own oral GLP-1 candidate, ribupatide (KAI-9531), which it licensed from Chinese developer Shanghai BrightGene.
The California Section 1782 Discovery Case
This European patent challenge provides the direct context for Kailera's ongoing federal litigation in the U.S. District Court for the Northern District of California (Kailera Therapeutics, Inc. v. Structure Therapeutics, Inc. et al., Case No. 3:2026mc80216).
Kailera has filed an ex parte application seeking Section 1782 discovery assistance, a federal statute that allows litigants in foreign proceedings to obtain evidence (documents and testimony) from entities located within the United States.
- If the California federal court rules in Kailera's favor, Structure and Gasherbrum Bio will be forced to hand over internal R&D documents, preclinical data, and communications regarding their oral GLP-1 chemical structures.
- Kailera intends to use this discovery as leverage to dismantle Structure's '183 patent in Europe, clearing a commercial path for ribupatide.
As of March 31, 2026, both companies are well-funded to sustain a prolonged legal battle:
- Structure Therapeutics holds $1.46 billion in cash, cash equivalents, and short-term investments, supported by an end-of-Phase 2 FDA meeting and its upcoming Q3 Phase 3 trial initiation.
- Kailera Therapeutics holds $111.8 million in cash (as of March 31, 2026, prior to its $625 million IPO proceeds), giving it a multi-year cash runway to fund both its clinical pipeline and its aggressive litigation strategy.